Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Jakob Ackermann

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Therapeutische Umschau. Revue Therapeutique|November 3, 2016
Christoph Jakob Ackermann, Ulrich Güller
Annals of Translational Medicine|February 5, 2020
Erlotinib plus bevacizumab for <i>EGFR</i>-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?Helen Adderley, Christoph Jakob Ackermann, Raffaele Califano
Translational Lung Cancer Research|February 2, 2019
Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancerRebecca Yin Tay, Christoph Jakob Ackermann, Raffaele Califano
Plos One|November 15, 2021
Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysisYael Rachamin, Christoph Jakob Ackermann, Oliver Senn, et al.
International Journal of Colorectal Disease|June 9, 2018
The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysisChristoph Jakob Ackermann, Ulrich Guller, Wolfram Jochum, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of lightChristoph Jakob Ackermann, Martin Reck, Luis Paz-Ares, et al.
Oncotargets and Therapy|October 3, 2019
Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future DirectionsChristoph Jakob Ackermann, Gustavo Stock, Rebecca Tay, et al.
Swiss Medical Weekly|July 28, 2017
Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resectionUlrich Güller, Rene Warschkow, Christoph Jakob Ackermann, et al.
International Journal of Cancer|June 19, 2023
Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasisGeorgios Tsakonas, Simon Ekman, Andreas Koulouris, et al.
Swiss Medical Weekly|January 30, 2018
Reply to technical comment on: Güller et al. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resectionUlrich Güller, Rene Warschkow, Christoph Jakob Ackermann, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Therapeutische Umschau. Revue Therapeutique|November 3, 2016
Christoph Jakob Ackermann, Ulrich Güller
Annals of Translational Medicine|February 5, 2020
Erlotinib plus bevacizumab for <i>EGFR</i>-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?Helen Adderley, Christoph Jakob Ackermann, Raffaele Califano
Translational Lung Cancer Research|February 2, 2019
Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancerRebecca Yin Tay, Christoph Jakob Ackermann, Raffaele Califano
Plos One|November 15, 2021
Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysisYael Rachamin, Christoph Jakob Ackermann, Oliver Senn, et al.
International Journal of Colorectal Disease|June 9, 2018
The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysisChristoph Jakob Ackermann, Ulrich Guller, Wolfram Jochum, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of lightChristoph Jakob Ackermann, Martin Reck, Luis Paz-Ares, et al.
Oncotargets and Therapy|October 3, 2019
Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future DirectionsChristoph Jakob Ackermann, Gustavo Stock, Rebecca Tay, et al.
Swiss Medical Weekly|July 28, 2017
Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resectionUlrich Güller, Rene Warschkow, Christoph Jakob Ackermann, et al.
International Journal of Cancer|June 19, 2023
Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasisGeorgios Tsakonas, Simon Ekman, Andreas Koulouris, et al.
Swiss Medical Weekly|January 30, 2018
Reply to technical comment on: Güller et al. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resectionUlrich Güller, Rene Warschkow, Christoph Jakob Ackermann, et al.
Pageof 2